IT HAS BEEN SHOWN that certain cytotoxic agents may be combined in such a way as to reduce normal-tissue toxicity (Millar & McElwain, 1978; Millar et al., 1978a,b; Hedley et al., 1978) . Such combinations take the form of a small pretreatment or "priming" dose of chemotherapeutic agent (usually cyclophosphamide, melphalan or cytosine arabinoside) followed at a fixed time by a large "challenge" dose of an alkylating agent or whole-body irradiation. The mechanism underlying this effect is not known.
A key question is whether tumours are similarly protected. In curability experiments conducted with Lewis lung carcinoma (Millar & McElwain, 1978) The end-point was tumour growth delay after treatment. Tumour volumes were calculated by measuring the greatest diameter (L) and the diameter perpendicular to the greatest diameter (D) and then applying the formula V = -rLD2/6. The growth rates of individual tumours were measured by comparing the volume at time t (Vt) with the pre-treatment volume (VO). The value Vt/V0 was calculated for each tumour at each sampling time, and a mean and standard error then calculated for each sampling time point from animals for each treatment group. Growth delay was calculated as the difference between treated and control tumours in time to reach twice the pre-treatment volume.
All drugs were administered i.p. Pure cyclophosphamide monohydrate (CY) (Endoxana, Koch-Light Ltd) was used dissolved in saline. Melphalan (Melph) (Alkeran, Burroughs WN'ellcome & Co.) was first dissolved in 1 ml of 2O% (v/v) acid alcohol and then in saline to the required concentration. Both solutions were prepared shortly before use.
In the first experiment animals were (a) left untreated, (b) treated with 300 mg/ kg CY alone, (c) given 50 mg/kg CY 4 days before 300 mg/kg CY, or (d) given 100 mg/ kg 4 days before 300 mg/kg CY. Four days had previously been shown to be the optimum interval in mice for decreasing normal-tissue toxicity, thus enhancing survival for this combination (Millar & McElwain, 1978) . All animals treated with 300 mg/kg CY alone died 3-14 days after treatment; tumour was present, in all of them but was not the cause of death. No animals died which had been pre-treated with either 50 or 100 mg/kg CY 4 days before 300 mg/kg.
In the second experiment melphalan was given as the challenge agent at 1a mg/ kg. CY was given as a pre-treatment at 2 dose levels, 50 or 100 mg/kg. The CY was given on Day 0 and melphalan on Day 2, as this is the time interval giving greatest protection of normal tissues with this combination (Millar et al., 1978a Fig. 1 shows the effect of the various treatments on tumour growth delay. In the group of animals treated with 300 mg/ kg CY alone, 3 animals died on Day 7, a 4th on Day 16 and the last on Day 18. A growth delay of 16 days was estimated, though in view of the mortality this value must be regarded with caution. Animals pre-treated with 50 mg/kg CY before 300 mg/kg cy all survived, as did the animals given 100 mg/kg CY before 300 mg/kg CY, and growth delays of 32 and 40 days respectively were measured. No complete regressions were seen in any of the groups.
In the second experiment, melphalan on its own produced a growth delay of 12 days (Fig. 2) 
